This website is for US healthcare professionals


Log In to Bolder Science


Don't have an account? Sign Up


Please enter your email address.

You will receive a link to create a new password via email.

Log In


Create an Account

  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma

  • identifier


  • Recruitment Status


  • First Posted

    April 30, 2019

  • Last update posted

    May 6, 2019

Study Description

Brief summary:

Zoledronic acid is an adjuvant treatment for primary osteosarcoma. Zoledronic acid has been widely used in the treatment of metastatic bone tumors. In addition to its inhibition of tumor osteoclasis, it also produces certain killing of tumor cells. effect. Foreign studies have shown that zoledronic acid also has a killing effect on osteosarcoma and has a certain inhibitory effect on distant metastasis. We hope that it can reduce tumor recurrence and lung metastasis through this study.

  • Condition or Disease:Tumor Necrosis
    Lung Metastases
  • Intervention/Treatment: Drug: Zoledronic Acid
  • Phase: Phase 4

Detailed Description


Study Design

  • Study Type: Interventional
  • Estimated Enrollment: 150 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Single (Participant)
  • Primary Purpose: Prevention
  • Official Title: The Efficacy of New Adjuvant Chemotherapy of Osteosarcoma Combined With Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma
  • Actual Study Start Date: January 2017
  • Estimated Primary Completion Date: January 2020
  • Estimated Study Completion Date: January 2023

Arms and interventions

Arm Intervention/treatment
Experimental: experimental group
Drug: Zoledronic Acid

Outcome Measures

  • Primary Outcome Measures: 1. rate of lung metastasis [ Time Frame: 3 year ]
    Discovery the rate of neonatal lung metastases by high-resolution chest CT
  • 2. rate of tumor recurrence [ Time Frame: 3 year ]
    Local recurrence rate of tumor or rate of distant metastasis
  • Secondary Outcome Measures: 1. rate of tumor necrosis less than 90% [ Time Frame: 3 year ]
    the rate of patients that postoperative tumor necrosis rate was estimated to be lower than grade III(90%)

Eligibility Criteria

  • Ages Eligible for Study: (Child, Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No


Inclusion Criteria:

- Patients with osteosarcoma who were diagnosed with initial pathology and pathology
were excluded from lung metastasis or other metastatic lesions by CT and total body
emission-computed tomography, and patients with standard chemotherapy were evaluated.

Exclusion Criteria:

- Pulmonary metastasis, pregnancy or lactation, renal insufficiency (creatinine
clearance <70 ml/min/1.73 m2), liver dysfunction, obvious oral disease, and unsuitable for bisphosphonate treatment after evaluation, have been found. With diseases that still require hormone therapy, abnormal blood system, heart disease

Contacts and Locations


Contact: Xiaobo Yan, Dr. +8613588153306


China, Zhejiang
2nd Affiliated Hospital of Zhejiang University

Sponsors and Collaborators

Second Affiliated Hospital, School of Medicine, Zhejiang University


Principal Investigator: zhaoming Ye, Prof. 2nd Affiliated Hospital Of Zhejiang University

More Information

  • Responsible Party: Second Affiliated Hospital, School of Medicine, Zhejiang University
  • Identifier: NCT03932071 History of Changes
  • Other Study ID Numbers: ChiCTR-IPR-16008568
  • First Posted: April 30, 2019 Key Record Dates
  • Last Update Posted: May 6, 2019
  • Last Verified: May 2019
  • Individual Participant
    Data (IPD) Sharing

  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Product Manufactured in and Exported from the U.S.: Yes
  • Additional relevant MeSH terms: Osteosarcoma Necrosis